Functionally, through T cell-mediated cancer cell killing assays and PD-L1/PD-1 binding assays, we demonstrated that FAT4 overexpression in tumor cells significantly activated CTL activity by downregulating PD-L1 levels. The gene discussed is FAT4; the disease is cancer.